Who should read this report?

Payers have historically shied away from restricting use of oncology medicines – and so executives in managed markets, marketing and brand-management, health economics and outcomes research, R&D planning and business development/M&A haven’t, in the past, had to clearly understand payer perspectives. No more.

• Market-Access Executives: Which plans will you focus on? What arguments will you have to learn to make?
• Marketing / Brand-Management: How must messaging and sales tactics change to be successful within new managed-care reimbursement policies?
• Health Economics and Outcomes Research: What studies should you be doing to best prepare the market?
• R&D Planning / Strategy: Is your diagnostic approach appropriate? Are the endpoints in your pivotal trials important to managed care?
• Business Development: Which areas should you be avoiding? What data should you insist on from your partner to satisfy emerging managed care concerns?